BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 for KRAS Mutant and HER2+ Cancers
Reuters
Oct 26
BridgeBio Oncology <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Launches Phase 1 Trial of BBO-10203 for KRAS Mutant and HER2+ Cancers
BridgeBio Oncology Therapeutics Inc. has announced new preclinical data for BBO-10203, a first-in-class, orally bioavailable selective inhibitor that blocks the interaction between RAS and PI3Kα. The data, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, demonstrate that BBO-10203 inhibits RAS-driven PI3Kα-AKT signaling in tumor cells without affecting glucose metabolism. The compound showed robust tumor growth inhibition as a monotherapy and in combination with BBOT's KRASG12C ON/OFF inhibitor, BBO-8520, and the panKRAS inhibitor, BBO-11818, in KRAS-mutant models at well-tolerated dose levels. BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, as well as KRAS mutant colorectal or non-small cell lung cancer, with initial Phase 1 clinical data expected in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9552043-en) on October 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.